Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
10.12.2025
Dec 10 (Reuters) - A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest. Patients in the trial had received initial treatments that eliminated nearly all of their cancer cells.